Clinical trial
A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
NCT01838876 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 29, 2013
- Completion date
- July 27, 2015
- Enrollment
- 442 (actual)
- Sites
- 90
Conditions
As the registry lists them; a condition with its own page is linked.